Clinical Trial Update: Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sintilimab and bevacizumab biosimilar in combination with pegylated liposomal doxorubicin for metastatic triple-negative bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN